Grady R M, Eisenberg P R, Bridges N D
Department of Pediatrics, Washington University School of Medicine, Saint Louis, Missouri.
J Am Coll Cardiol. 1995 Mar 1;25(3):725-9. doi: 10.1016/0735-1097(94)00438-V.
We sought to determine an anticoagulation protocol for use during cardiac catheterization in children.
There are few data to indicate which dose of heparin represents adequate anticoagulation or how best to monitor its efficacy. In this study, adequate anticoagulation was defined as the amount of heparin needed to prevent a significant increase in serum fibrinopeptide A, a sensitive marker for thrombin activity. The degree of heparinization was estimated by the activated clotting time.
Thirty-six children (1 month to 19.5 years old) with congenital heart disease underwent diagnostic cardiac catheterization; 13 of these 36 patients had an additional interventional procedure. Sheaths and catheters were flushed with heparinized saline (1 IU/ml); during the procedure, 33 of the 36 patients received either a 50- or a 100-IU/kg heparin bolus. Paired fibrinopeptide A and activated clotting time samples were obtained throughout each procedure.
Increasing the activated clotting time with heparin resulted in a dose-related decrease in fibrinopeptide A levels. A single heparin bolus of either 50 or 100 IU/kg elevated the activated clotting time above baseline level (209 +/- 52 s after 50 IU/kg, 270 +/- 57 s after 100 IU/kg vs. 133 +/- 20 s at baseline [p < 0.0001]) and reduced fibrinopeptide A levels below baseline (7.9 +/- 14 ng/ml after 50 IU/kg, 4.8 +/- 3.7 ng/ml after 100 IU/kg vs. 38 +/- 59 ng/ml at baseline [p < 0.0001]). Heparin flush alone did not increase the activated clotting time above baseline and failed to suppress an increase in fibrinopeptide A levels. There were no differences in activated clotting time and fibrinopeptide A values between patients undergoing diagnostic or interventional procedures.
Administration of a heparin bolus to maintain an activated clotting time > 200 s prevented a significant increase in thrombin activity. Heparin flush alone did not provide adequate anticoagulation. Patients undergoing an interventional procedure did not require more heparin than that needed for a diagnostic procedure.
我们试图确定一种适用于儿童心导管插入术的抗凝方案。
几乎没有数据表明哪种肝素剂量能实现充分抗凝,或如何最佳地监测其疗效。在本研究中,充分抗凝被定义为预防血清纤维蛋白肽A显著增加所需的肝素量,血清纤维蛋白肽A是凝血酶活性的敏感标志物。肝素化程度通过活化凝血时间来估计。
36名患有先天性心脏病的儿童(年龄1个月至19.5岁)接受了诊断性心导管插入术;这36名患者中有13名还接受了介入手术。鞘管和导管用肝素盐水(1 IU/ml)冲洗;在手术过程中,36名患者中的33名接受了50或100 IU/kg的肝素推注。在每个手术过程中全程采集配对的纤维蛋白肽A和活化凝血时间样本。
用肝素增加活化凝血时间导致纤维蛋白肽A水平呈剂量相关下降。单次50或100 IU/kg的肝素推注使活化凝血时间高于基线水平(50 IU/kg后为209±52秒,100 IU/kg后为270±57秒,而基线时为133±20秒[p<0.0001]),并使纤维蛋白肽A水平低于基线(50 IU/kg后为7.9±14 ng/ml,100 IU/kg后为4.8±3.7 ng/ml,而基线时为38±59 ng/ml[p<0.0001])。单独的肝素冲洗未使活化凝血时间高于基线水平,也未能抑制纤维蛋白肽A水平的升高。接受诊断性或介入性手术的患者之间活化凝血时间和纤维蛋白肽A值无差异。
给予肝素推注以维持活化凝血时间>200秒可预防凝血酶活性显著增加。单独的肝素冲洗不能提供充分抗凝。接受介入手术的患者所需的肝素量并不比诊断性手术更多。